Loading...
•
Jun 30, 2021
Medpace Q2 2021 Earnings Report
Medpace's revenue increased, driven by net new business awards and backlog conversion.
Key Takeaways
Medpace Holdings, Inc. reported a strong second quarter in 2021, with revenue increasing by 35.8% to $278.3 million compared to the prior-year period. Net new business awards grew by 52.5% to $387.6 million, resulting in a net book-to-bill ratio of 1.39x. GAAP net income increased to $39.9 million, or $1.06 per diluted share, compared to $24.1 million, or $0.64 per diluted share, in the prior-year period.
Revenue for Q2 2021 increased 35.8% to $278.3 million compared to Q2 2020.
Net new business awards were $387.6 million in Q2 2021, a 52.5% increase year-over-year.
GAAP net income for Q2 2021 was $39.9 million, or $1.06 per diluted share, compared to $24.1 million, or $0.64 per diluted share, for the comparable prior-year period.
Cash and cash equivalents were $339.0 million as of June 30, 2021, and the company generated $62.8 million in cash flow from operating activities during the second quarter of 2021.
Medpace
Medpace
Forward Guidance
The Company forecasts 2021 revenue in the range of $1.110 billion to $1.150 billion, representing growth of 19.9% to 24.2% over 2020 revenue of $925.9 million. GAAP net income for full year 2021 is forecasted in the range of $162.5 million to $169.5 million. Additionally, full year 2021 EBITDA is expected in the range of $205.0 million to $215.0 million. Based on forecasted 2021 revenue of $1.110 billion to $1.150 billion and GAAP net income of $162.5 million to $169.5 million, diluted earnings per share (GAAP) is forecasted in the range of $4.31 to $4.50.
Positive Outlook
- Revenue is forecasted between $1.110 billion and $1.150 billion.
- Revenue growth of 19.9% to 24.2% over 2020 revenue.
- GAAP net income is forecasted between $162.5 million and $169.5 million.
- EBITDA is expected to be in the range of $205.0 million to $215.0 million.
- Diluted earnings per share (GAAP) is forecasted in the range of $4.31 to $4.50.
Challenges Ahead
- Guidance assumes a full year 2021 tax rate of 11.0% to 12.0%.
- Guidance does not reflect the potential impact of any share repurchases the Company may make pursuant to the share repurchase program after June 30, 2021.
- Potential loss, delay or non-renewal of contracts.
- Failure to convert backlog to revenue.
- Risks related to disruptions due to pandemics.